HRP20180285T1 - Novi 4,6-disupstituirani derivati aminopirimidina - Google Patents
Novi 4,6-disupstituirani derivati aminopirimidina Download PDFInfo
- Publication number
- HRP20180285T1 HRP20180285T1 HRP20180285TT HRP20180285T HRP20180285T1 HR P20180285 T1 HRP20180285 T1 HR P20180285T1 HR P20180285T T HRP20180285T T HR P20180285TT HR P20180285 T HRP20180285 T HR P20180285T HR P20180285 T1 HRP20180285 T1 HR P20180285T1
- Authority
- HR
- Croatia
- Prior art keywords
- methoxyphenyl
- pyrimidin
- ylamino
- alkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Spoj formule (I):
[image]
,
gdje su X, Y i Z H, F ili Cl;
R1 je OR, gdje je R vodik ili skupina koju se bira između nerazgranatog ili razgranatog C1-C6 alkila, C2-C6 alkenila, C2-C6 alkinila, C3-C6 cikloalkila, heterociklila, CF3, CCl3 i arila na položajima 2, 3 ili 4;
R2 je OH, alkoksi, ariloksi, CH2OR (gdje je R H, nerazgranati ili razgranati aril, cikloalkil ili alkil), CH2NR′R″ (gdje su R′ i R″ neovisno H, nerazgranati ili razgranati aril, cikloalkil ili alkil), CHO, OCOW (gdje je W nerazgranati ili razgranati aril ili alkil ili C-(halogen)3), CONR′R″ (gdje su R′ i R″ neovisno H, alkil, cikloalkil ili aril), COOR (gdje je R H, alkil, cikloalkil ili aril), CH2NHSO2R (gdje je R H, alkil, cikloalkil ili aril), Cl, Br, F, CH2-N-benzimidazol, CONHNR′R″ (gdje su R′ i R″ neovisno H, alkil, cikloalkil ili aril), NRCOOR′ (gdje su R i R′ neovisno H, alkil, cikloalkil ili aril), NH2, NR′R″ (gdje su R′ i R″ neovisno alkil, cikloalkil ili aril), NHCOR (gdje je R H, alkil, cikloalkil ili aril), nitro, OCH2CH2-heterociklil, OCOR (gdje je R H, alkil, cikloalkil ili aril), OCONR′R″ (gdje su R′ i R″ neovisno H, alkil, cikloalkil ili aril), OCOOR (gdje je R H, alkil, cikloalkil ili aril), NHCOOCH2C-halogen3, NRCONR′R″ (gdje su R, R′ i R″ neovisno H, alkil, cikloalkil ili aril), NHSO2R (gdje je R H, alkil, cikloalkil ili aril), NHSO2NR′R″ (gdje su R′ i R″ neovisno H, alkil, cikloalkil ili aril),
[image]
,
[image]
,
[image]
,
[image]
;
i R3 je OH, alkoksi, ariloksi, NR′R″ (gdje su R′ i R″ H), NHCOR (gdje je R H, alkil, cikloalkil ili aril) i CONR′R″ (gdje su R′ i R″ neovisno H, alkil, cikloalkil ili aril).
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R1 OR, gdje je R H, metil, izopropil ili etil.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R1 2′-OR, gdje je R H, metil, etil ili izopropil.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Z H ili F.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R2 bira iz skupine koju čine OH, nerazgranati ili razgranati alkoksi, CH2OR (gdje je R alkil), NH2, CH2NH2, OCOC(CH3)3, CONH2, Cl, Br, CH2-N-benzimidazol, NHSO2R (gdje je R alkil ili aril) i NHSO2NR′R″ (gdje su R′ i R″ neovisno H, alkil, ili aril), OCH2CH2-heterociklil, OCOR (gdje je R H, alkil, cikloalkil ili aril), OCONR′R″ (gdje su R′ i R″ neovisno H, alkil, cikloalkil ili aril).
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R3 OH, nerazgranati ili razgranati alkoksi, NR′R″ (gdje su R′ i R″ H), CONR′R″ (gdje su R′ i R″ neovisno H, alkil, cikloalkil ili aril).
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R2 bira iz skupine koju čine OH, nerazgranati ili razgranati alkoksi, CONH2, OCOC(CH3)3, Cl, CH2-N-benzimidazol, a R3 se bira iz skupine koju čine alkoksi.
8. Spoj u skladu s patentnim zahtjevom 1, naznačen time što su X, Y i Z H ili F, R2 je nerazgranati ili razgranati alkoksi, CONH2, OCOC(CH3)3, Cl, CH2-N-benzimidazol, a R3 je alkoksi.
9. Spoj u skladu s patentnim zahtjevom 1, naznačen time što su X, Y i Z H ili F, R1 je metoksi ili etoksi, R2 je nerazgranati ili razgranati alkoksi, CONH2, Cl, Br, CH2-N-benzimidazol, a R3 je alkoksi.
10. Spoj u skladu s patentnim zahtjevom 1, naznačen time što su X i Y 4′-F, 5′-F ili H, Z je 2′-F ili H, R1 je 2′-OR, gdje je R H, metil, etil ili izopropil, R2 je nerazgranati ili razgranati alkoksi, CONH2, Cl, Br, CH2-N-benzimidazol, a R3 je OR′ (gdje je R′ alkil).
11. Farmaceutski pripravak, naznačen time što sadrži farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili podlogu i terapijski djelotvornu količinu spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 10.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što ga se bira između:
2-metoksi-N4-[6-(2-metoksifenil)pirimidin-4-il]benzen-1,4-diamina (Primjer 59);
metil-2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino]benzoat (Primjer 30);
N1-[6-(4-fluor-2-metoksifenil)pirimidin-4-il]-4-metoksibenzen-1,3-diamina (Primjer 64);
4-fluor-6-metoksi-N3-[6-(2-metoksifenil)pirimidin-4-il]benzen-1,3-diamina (Primjer 92);
4-fluor-5-[6-(5-fluor-2-metoksifenil)pirimidin-4-ilamino]-2-metoksibenzamida (Primjer 144);
2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)fenil-pivalata (Primjer 26);
5-[6-(4-fluor-2-metoksifenil)pirimidin-4-ilamino]-2-metoksifenola (Primjer 123);
N-(3-(benziloksi)-4-metoksifenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 36);
N-(3-fluor-4-metoksifenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 22);
2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)fenola (Primjer 32);
4-metoksi-N1-(6-(2-metoksifenil)pirimidin-4-il)benzen-1,3-diamina (Primjer 41);
2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)benzamida (Primjer 45);
metilnog estera {2-metoksi-5-[6-(2-metoksifenil)pirimidin-4-ilamino]fenil}karbaminske kiseline (Primjer 51);
(2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)fenil)(metilsulfamoil)amina (Primjer 10);
N-benzil-2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)benzamida (Primjer 23);
(2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)fenil)metanola (Primjer 24);
2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)-N-metilbenzamida (Primjer 25);
N-(4-metoksi-3-nitrofenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 11);
N1-[6-(2-izopropoksifenil)pirimidin-4-il]-4-metoksibenzen-1,3-diamina (Primjer 79);
N-(3-((dimetilamino)metil)-4-metoksifenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 35);
N-(4-metoksi-3-((fenilamino)metil)fenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 34);
2-(2-metoksi-5-(6-(2-metoksifenil)pirimidin-4-ilamino)benzil)izoindolin-1,3-diona (Primjer 3);
4-fluor-5-[6-(4-fluor-2-metoksifenil)pirimidin-4-ilamino]-2-metoksibenzamida (Primjer 146);
5-[6-(4-fluor-2-metoksifenil)pirimidin-4-ilamino]-2-metoksibenzamida (Primjer 128);
4-fluor-2-metoksi-5-[6-(2-metoksifenil)pirimidin-4-ilamino]benzamida (Primjer 143);
5-[6-(2-etoksifenil)pirimidin-4-ilamino]-4-fluor-2-metoksibenzamida (Primjer 145);
5-[6-(2-etoksi-4-fluorfenil)pirimidin-4-ilamino]-4-fluor-2-metoksibenzamida (Primjer 147);
4-(6-(2-metoksifenil)pirimidin-4-ilamino)-2-nitrofenola (Primjer 12);
N-(3-((benzilamino)metil)-4-metoksifenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 1);
N-(3-(aminometil)-4-metoksifenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 43);
3-fluor-5-[6-(4-fluor-2-metoksifenil)pirimidin-4-ilamino]-2-metoksibenzamida (Primjer 138); i
3-fluor-5-[6-(5-fluor-2-metoksifenil)pirimidin-4-ilamino]-2-metoksibenzamida (Primjer 140).
13. Spoj, naznačen time što ga se bira između
2-dimetilamino-5-[6-(4-fluor-2-metoksifenil)pirimidin-4-ilamino]benzamida (Primjer 113);
2-(2-klor-5-(6-(2-metoksifenil)pirimidin-4-ilamino)benzil)izoindolin-1,3-diona (Primjer 20);
etil-2-klor-5-(6-(2-metoksifenil)pirimidin-4-ilamino)benzoata (Primjer 14);
2-dluor-N4-[6-(2-metoksifenil)pirimidin-4-il]-N1,N1-dimetilbenzen-1,4-diamina (Primjer 106);
2-dimetilamino-5-[6-(2-metoksifenil)pirimidin-4-ilamino]fenola (Primjer 108);
2-dimetilamino-5-[6-(2-metoksifenil)pirimidin-4-ilamino]benzamida (Primjer 109);
etil-5-(6-(2-metoksifenil)pirimidin-4-ilamino)-2-morfolinobenzoata (Primjer 18);
2-klor-5-(6-(2-metoksifenil)pirimidin-4-ilamino)benzamida (Primjer 44); i
N-(3-((1H-benzo[d]imidazol-1-il)metil)-4-(4-metilpiperazin-1-il)fenil)-6-(2-metoksifenil)pirimidin-4-amina (Primjer 2).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692641P | 2012-08-23 | 2012-08-23 | |
| PCT/US2013/056347 WO2014031937A1 (en) | 2012-08-23 | 2013-08-23 | Novel 4,6-disubstituted aminopyrimidine derivatives |
| EP13831626.0A EP2887943B1 (en) | 2012-08-23 | 2013-08-23 | Novel 4,6-disubstituted aminopyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180285T1 true HRP20180285T1 (hr) | 2018-04-20 |
Family
ID=50148518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180285TT HRP20180285T1 (hr) | 2012-08-23 | 2013-08-23 | Novi 4,6-disupstituirani derivati aminopirimidina |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9617225B2 (hr) |
| EP (1) | EP2887943B1 (hr) |
| JP (2) | JP6639231B2 (hr) |
| KR (1) | KR102209229B1 (hr) |
| CN (1) | CN104822380B (hr) |
| AU (1) | AU2013305634B2 (hr) |
| BR (1) | BR112015003655A2 (hr) |
| CA (1) | CA2882733C (hr) |
| DK (1) | DK2887943T3 (hr) |
| EA (1) | EA029278B1 (hr) |
| ES (1) | ES2661717T3 (hr) |
| HR (1) | HRP20180285T1 (hr) |
| HU (1) | HUE036288T2 (hr) |
| IL (2) | IL237143A (hr) |
| LT (1) | LT2887943T (hr) |
| MX (1) | MX355354B (hr) |
| NO (1) | NO2970314T3 (hr) |
| NZ (1) | NZ705313A (hr) |
| PL (1) | PL2887943T3 (hr) |
| SG (2) | SG11201501041VA (hr) |
| SI (1) | SI2887943T1 (hr) |
| TR (1) | TR201802913T4 (hr) |
| UA (1) | UA117814C2 (hr) |
| WO (1) | WO2014031937A1 (hr) |
| ZA (1) | ZA201501600B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015003655A2 (pt) * | 2012-08-23 | 2017-07-04 | Virostatics Srl | composto; uso de um composto; e composição farmacêutica |
| CN104151178B (zh) * | 2014-08-06 | 2016-08-17 | 江苏鼎龙科技有限公司 | 2-氨基-4-(β-羟乙基氨基)苯甲醚及其硫酸盐的制备方法 |
| EP3207037B1 (en) | 2014-10-16 | 2019-01-23 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group |
| KR20180012853A (ko) | 2015-06-16 | 2018-02-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 |
| EP3356373B1 (en) | 2015-09-29 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic sulfondiimine compounds |
| ES2819869T3 (es) | 2015-10-08 | 2021-04-19 | Bayer Pharma AG | Nuevos compuestos macrocíclicos modificados |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP3190103A1 (en) * | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| US11254690B2 (en) | 2017-03-28 | 2022-02-22 | Bayer Pharma Aktiengesellschaft | PTEFb inhibiting macrocyclic compounds |
| US11242356B2 (en) | 2017-03-28 | 2022-02-08 | Bayer Aktiengesellschaft | PTEFb inhibiting macrocyclic compounds |
| CN109761909B (zh) * | 2019-01-25 | 2022-08-26 | 中国药科大学 | N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途 |
| IT201900004737A1 (it) | 2019-03-29 | 2020-09-29 | Virostatics Srl | Composti aventi attività enzimatica anti-CDK4/6 e anti-CDK9 per l’inibizione della proliferazione del cancro e relativi metodi di screening per la loro identificazione. |
| CN111269215B (zh) * | 2020-04-01 | 2021-10-26 | 中科利健制药(广州)有限公司 | 含氮杂环有机化合物及其制备方法和应用 |
| KR20230038740A (ko) * | 2020-08-07 | 2023-03-21 | 파마블럭 사이언시스 (난징), 인코포레이티드 | Cdk9 억제제 및 이의 용도 |
| WO2022195522A1 (en) * | 2021-03-17 | 2022-09-22 | Ildong Pharmaceutical Co., Ltd. | Inhibitors of ano6 and their uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| US6757135B2 (en) | 2000-07-28 | 2004-06-29 | Seagate Technology Llc | Leading edge bond pads |
| WO2002012198A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| US7419984B2 (en) * | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| EA013811B1 (ru) * | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| CA2533474A1 (en) * | 2003-07-30 | 2005-02-10 | Shudong Wang | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| WO2006125616A2 (en) | 2005-05-25 | 2006-11-30 | Ingenium Pharmaceuticals Ag | Pyrimidine-based cdk inhibitors for treating pain |
| US8507498B2 (en) * | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| HU0900798D0 (en) | 2009-12-21 | 2010-03-01 | Vichem Chemie Kutato Kft | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity |
| WO2013175415A1 (en) * | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
| BR112015003655A2 (pt) * | 2012-08-23 | 2017-07-04 | Virostatics Srl | composto; uso de um composto; e composição farmacêutica |
-
2013
- 2013-08-23 BR BR112015003655A patent/BR112015003655A2/pt not_active Application Discontinuation
- 2013-08-23 EA EA201590417A patent/EA029278B1/ru unknown
- 2013-08-23 SI SI201330960T patent/SI2887943T1/en unknown
- 2013-08-23 SG SG11201501041VA patent/SG11201501041VA/en unknown
- 2013-08-23 NZ NZ705313A patent/NZ705313A/en not_active IP Right Cessation
- 2013-08-23 HR HRP20180285TT patent/HRP20180285T1/hr unknown
- 2013-08-23 UA UAA201502548A patent/UA117814C2/uk unknown
- 2013-08-23 WO PCT/US2013/056347 patent/WO2014031937A1/en active Application Filing
- 2013-08-23 AU AU2013305634A patent/AU2013305634B2/en active Active
- 2013-08-23 HU HUE13831626A patent/HUE036288T2/hu unknown
- 2013-08-23 MX MX2015002270A patent/MX355354B/es active IP Right Grant
- 2013-08-23 CA CA2882733A patent/CA2882733C/en active Active
- 2013-08-23 CN CN201380044228.4A patent/CN104822380B/zh active Active
- 2013-08-23 ES ES13831626.0T patent/ES2661717T3/es active Active
- 2013-08-23 LT LTEP13831626.0T patent/LT2887943T/lt unknown
- 2013-08-23 SG SG10201701438QA patent/SG10201701438QA/en unknown
- 2013-08-23 TR TR2018/02913T patent/TR201802913T4/tr unknown
- 2013-08-23 PL PL13831626T patent/PL2887943T3/pl unknown
- 2013-08-23 US US13/974,228 patent/US9617225B2/en not_active Expired - Fee Related
- 2013-08-23 EP EP13831626.0A patent/EP2887943B1/en active Active
- 2013-08-23 DK DK13831626.0T patent/DK2887943T3/en active
- 2013-08-23 JP JP2015528679A patent/JP6639231B2/ja not_active Expired - Fee Related
- 2013-08-23 KR KR1020157007244A patent/KR102209229B1/ko active Active
-
2014
- 2014-03-12 NO NO14717576A patent/NO2970314T3/no unknown
-
2015
- 2015-02-08 IL IL237143A patent/IL237143A/en not_active IP Right Cessation
- 2015-03-09 ZA ZA2015/01600A patent/ZA201501600B/en unknown
-
2017
- 2017-02-25 US US15/442,651 patent/US10294218B2/en active Active
- 2017-06-21 IL IL253061A patent/IL253061B/en active IP Right Grant
-
2018
- 2018-06-06 JP JP2018108829A patent/JP6781736B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180285T1 (hr) | Novi 4,6-disupstituirani derivati aminopirimidina | |
| PE20091033A1 (es) | Derivados de nicotinamida como agentes anticancerosos y su preparacion | |
| KR100863849B1 (ko) | 디아민 유도체, 그 제조방법 및 그것을 유효 성분으로 하는식물 병해 방제제 | |
| RS54505B1 (en) | HETEROARYL PYRIDONE AND AZA-PYRIDONE UNITS AS BTK ACTIVITY INHIBITORS | |
| RS53176B (en) | KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS | |
| PE20160654A1 (es) | Compuestos de inhibidor de autotaxina | |
| RS50672B (sr) | Postupak za pripremanje n-fenilpirazol-1-karboksamida | |
| NZ605988A (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
| HRP20160533T1 (hr) | Indoli kao antivirusna sredstva respiratornog sincicijskog virusa | |
| HRP20170311T1 (hr) | Novi spojevi pirolopirimidina kao inhibitori protein kinaza | |
| RS54375B1 (en) | TIOACETATE UNITS, COMPOSITIONS AND USE PROCEDURES | |
| RS51545B (en) | THIAZOL PIRAZOLOPIRAMIDINS AS ANTAGONISTS OF CRF1 RECEPTORS | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| RS53081B (en) | THIAZOLOPYRIDIN-2-ILOXY-PHENYL I AMINI THIAZOLOPYRIDIN-2-ILOXY-PHENYL KAO MODULATOR LEUKOTRIEN A4 HYDROLAZE | |
| RS53688B1 (en) | 1,2,5-OXADIAZOLES AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | |
| JP2017504576A5 (hr) | ||
| HRP20211002T1 (hr) | 1,3-tiazol-2-il supstituirani benzamidi | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| RS53019B (en) | DERIVATIVES OF ADAMANTYL DIAMIDE AND THEIR USE | |
| RS53266B (en) | PHARMACEUTICAL FORMULATION | |
| CY1112011T1 (el) | Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης | |
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| DK2078026T3 (da) | Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf | |
| RS52451B (en) | PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE | |
| PE20140421A1 (es) | COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2 |